Simple SummaryThis study examined reasons why adopters chose their pet in an animal shelter, what behaviors were first exhibited by the pet to the adopter, what information was important during their selection process, and the relative importance of seeing the animals’ behavior in various contexts.AbstractResponses from an adopter survey (n = 1,491) determined reasons for pet selection, type of information received by the adopter, and the context in which the animal’s behavior was observed. Appearance of the animal, social behavior with adopter, and personality were the top reasons for adoption across species and age groups. Most adopters stated that information about the animal from a staff member or volunteer was more important than information on cage cards, and health and behavior information was particularly important. Adopters found greater importance in interacting with the animal rather than viewing it in its kennel. The results of this study can be used by shelters to create better adoption matches, prioritize shelter resources and staff training, and potentially increase adoptions. Additionally, some simple training techniques are suggested to facilitate adopter-friendly behaviors from sheltered dogs and cats.

BK virus-associated nephropathy (PvAN) increases the risk of graft failure justifying treatment. Conversion to mammalian target of rapamycin inhibitors (mTORi) and Human polyclonal immunoglobulins (IVIg) could prevent the risk of PvAN. Our retrospective study assessed the efficacy of mTORi associated with IVIg therapy (mTORi±IVIg group) versus standard immunosuppression reduction to clear BKV DNAemia. Among forty-three kidney-transplanted patients with positive BKV DNAemia, we included twenty-six patients in the mTORi±IVIg group and reduced immunosuppression therapy for seventeen patients. We focused on BKV DNAemia clearance on the first-year. Renal function, rejection rate, evolution to PvAN, and complications of immunosuppression were assessed. BKV DNAemia decreased faster and significantly in the control group as compared to the mTORi±IVIg group (p < 0.001). Viral clearance was significantly higher in the control group compared to the mTORi±IVIg group (88% vs. 58%; p = 0.033). Death-censored graft loss, rejection rates and kidney-graft function at 12 months did not significantly differ. Multivariate analyses significantly associated BKV DNAemia clearance with reducing immunosuppression (OR = 0.11 (0.06–0.9), p = 0.045), female kidney donor (OR = 0.10 (0.01–0.59/)], p = 0.018) and time to first DNAemia, (OR = 0.88 (0.76–0.96), p = 0.019). In our study, the standard treatment for BKV DNAemia had better outcomes than an mTORi±IVIg conversion.